Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Palisade Bio ( (PALI) ) has shared an update.
On July 23, 2025, Palisade Bio entered into a warrant inducement agreement with an accredited holder to exercise existing warrants at a reduced price of $0.9047 per share, resulting in the issuance of 4,318,905 shares of common stock and generating approximately $3.9 million in gross proceeds. The agreement includes the issuance of new warrants for additional shares, subject to stockholder approval, and aims to provide working capital and support corporate purposes, with Ladenburg Thalmann & Co. Inc. acting as the exclusive placement agent.
The most recent analyst rating on (PALI) stock is a Buy with a $22.50 price target. To see the full list of analyst forecasts on Palisade Bio stock, see the PALI Stock Forecast page.
Spark’s Take on PALI Stock
According to Spark, TipRanks’ AI Analyst, PALI is a Neutral.
Palisade Bio’s financial struggles dominate the overall assessment with consistent losses and negative cash flow posing significant risks. Despite a stable balance sheet due to low leverage, the lack of profitability and reliance on external funding are concerning. Technical analysis shows some short-term stability, but long-term trends are negative, and valuation metrics are weak due to the negative P/E ratio.
To see Spark’s full report on PALI stock, click here.
More about Palisade Bio
Palisade Bio is a clinical-stage biopharmaceutical company focused on developing and advancing novel therapeutics for patients living with autoimmune, inflammatory, and fibrotic diseases.
Average Trading Volume: 560,382
Technical Sentiment Signal: Sell
Current Market Cap: $5.32M
See more data about PALI stock on TipRanks’ Stock Analysis page.